Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol

• Status: Unknown status
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Confirm central blood pressure reduction effect of Fimasartan, Valsartan and Atenolol and compare correlation with the measured peripheral (central blood pressure, pulse wave velocity, and flow-mediated dilation) and cerebral blood flow factors (transcranial doppler findings, cerebral blood flow volume) in acute ischemic stroke patients with hypertension.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ajou University School of Medicine
• Collaborator: Boryung Pharmaceutical Co., Ltd
• Treatments: Atenolol; Valsartan

Criteria

Inclusion Criteria:

• Age ≥ 30 years old

• Acute ischemic stroke patient who has corresponding DWI(diffusion- weighted imaging) lesion correlated with symptom

• after 7days, but within 28days from stroke onset

• Diagnosed with Hypertension

• hypertensive patients who taking anti-hypertensive drugs or SBP≥140mmHg

• Informed consent

Exclusion Criteria:

• Patients with hemorrhagic Stroke

• Patients with severe Stroke - over NIHss(National Institutes of Health stroke scale) 16

• Uncontrolled hypertension (SBP ≥200mmHg)

• Patients with history of allergic reaction to any angiotensin II antagonist

• Liver disease(more than double to normal level, SGOT(serum glutamic-oxaloacetic transaminase ), SGPT(serum glutamic-pyruvic transaminase ), total bilirubin)

• Renal disease(serum creatinine ≥2.0mg/dl)

• Anemia(Hb < 8mg/dl)

• Thrombocytopenia( < 10^3/ml)

• Patients with secondary hypertension

• Childbearing and breast-feeding women

• Otherwise inappropriate patients depending on the investigator's decision